Nitric Oxide Therapy

1998 ◽  
pp. 218-220
Keyword(s):  
Nitric Oxide ◽  
Nitric Oxide Therapy

scholarly journals Nitric Oxide Therapy for Diabetic Wound Healing

2019 ◽  
Vol 8 (12) ◽  
pp. 1801210 ◽  
Author(s):  
Maggie J. Malone‐Povolny ◽  
Sara E. Maloney ◽  
Mark H. Schoenfisch
Keyword(s):  
Nitric Oxide ◽  
Wound Healing ◽  
Diabetic Wound ◽  
Diabetic Wound Healing ◽  
Nitric Oxide Therapy

Monitoring environmental NOx during Inhaled Nitric Oxide Therapy

2021 ◽  
Vol 84 ◽  
pp. 304
Author(s):  
Frank Kirrane ◽  
Maire Ahern ◽  
Mary Maguire ◽  
Miriam Byrne
Keyword(s):  
Nitric Oxide ◽  
Inhaled Nitric Oxide ◽  
Nitric Oxide Therapy

The effect of inhaled nitric oxide therapy on thromboelastogram in newborns with persistent pulmonary hypertension

2014 ◽  
Vol 173 (10) ◽  
pp. 1381-1385 ◽  
Author(s):  
Sema Tanriverdi ◽  
Ozge Altun Koroglu ◽  
Ozgun Uygur ◽  
Can Balkan ◽  
Mehmet Yalaz ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Pulmonary Hypertension ◽  
Inhaled Nitric Oxide ◽  
Persistent Pulmonary Hypertension ◽  
Nitric Oxide Therapy

Persistent Pulmonary Hypertension of the Newborn: Role of Nitric Oxide

1995 ◽  
Vol 10 (6) ◽  
pp. 270-282
Author(s):  
Stella Kourembanas
Keyword(s):  
Nitric Oxide ◽  
Pulmonary Hypertension ◽  
Structural Changes ◽  
Critical Role ◽  
Persistent Pulmonary Hypertension ◽  
Cell Contractility ◽  
Vasoactive Mediators ◽  
Nitric Oxide Therapy

Persistent pulmonary hypertension of the newborn (PPHN) is a common cause of respiratory failure in the full-term neonate. Molecular and cellular studies in vascular biology have revealed that endothelial-derived mediators play a critical role in the pathogenesis and treatment of PPHN. Endothelial-derived vasoconstrictors, like endothelin, may increase smooth muscle cell contractility and growth, leading to the physiologic and structural changes observed in the pulmonary arterioles of infants with this disease. On the other hand, decreased production of the endothelial-derived relaxing factor, nitric oxide, may exacerbate pulmonary vasoreactivity and lead to more severe pulmonary hypertension. Exogenous (inhaled) nitric oxide therapy reduces pulmonary vascular resistance and improves oxygenation. The safety and efficacy of this therapy in reducing the need for extracorporeal membrane oxygenation and decreasing long-term morbidity is being tested in several trials nationally and abroad. Understanding the basic mechanisms that regulate the gene expression and production of these vasoactive mediators will lead to improved preventive and therapeutic strategies for PPHN.

ERRATA

PEDIATRICS ◽  
1993 ◽  
Vol 92 (1) ◽  
pp. 190-190
Keyword(s):  
Nitric Oxide ◽  
Front Cover ◽  
Nitric Oxide Therapy

On the front cover of the May 1993 issue of Pediatrics, the title of the commentary by Kinsella and Abman should read "Inhalational Nitric Oxide Therapy for PPHN."

Sign in / Sign up

Export Citation Format

Share Document